Abstract
Background: Lung cancer is till one of the leading causes of cancer-related deaths and lung adenocarcinoma is the most common type. Compared with invasive adenocarcinoma, adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) are considered as indolent lung adenocarcinoma with good prognosis. However, AIS, MIA and even some early-stage invasive adenocarcinoma can be shown as pure ground-glass nodules on computed tomorgraphy images, which is quite difficult for clinicians to make a precise diagnosis and a suitable treatment plan. Thus, we aim to investigate the performance of radiomic-based quantitative analysis on CT images in identifying invasiveness of lung adenocarcinoma manifesting as pure ground-glass nodules. Methods: 275 lung adenocarcinoma cases with 322 pure ground-glass nodules from January 2015 to October 2017 were enrolled in this retrospective study. All lesions were resected surgically and confirmed pathologically. Clinical data like age, gender, smoking status of all cases were collected from digital medical records. Radiomic feature extraction was performed using Python with semi-automatically segmented tumor regions on CT scans which was contoured with an in-house developed plugin for 3D-Slicer. The predictive performance of the prediction models was evaluated through the receiver operating characteristic curve (ROC). Results: Among 322 nodules, 48(15%) were Adenocarcinoma in situ (AIS), 102(32%) were minimally invasive adenocarcinoma (MIA) and 172(53%) were invasive adenocarcinoma. All nodules were divided into training and validation cohort randomly with a ratio of 2:1 to establish prediction models. The values of the area under the curve were 0.716 (95%CI:0.600 0.832) and 0.827 (95%CI:0.729 0.925) with the diagnostic accuracy of 59.3% and 69.1% for radiomic and combined models, respectively. Conclusions: Radiomic model built via quantitative CT analysis can help to identify the invasiveness of lung adenocarcinoma represented as pure ground-glass nodules. Combining this model with clinical features can significantly improve its prediction performance. Legal entity responsible for the study: Fangyi Xv. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.